作者
Tine Cuppens, Daniela Annibali, An Coosemans, Jone Trovik, Natalja Ter Haar, Eva Colas, Angel Garcia-Jimenez, Koen Van de Vijver, Roy PM Kruitwagen, Mariel Brinkhuis, Michal Zikan, Pavel Dundr, Jutta Huvila, Olli Carpen, Johannes Haybaeck, Farid Moinfar, Helga B Salvesen, Maciej Stukan, Carole Mestdagh, Ronald P Zweemer, Leonardus F Massuger, Michael R Mallmann, Eva Wardelmann, Miriam Mints, Godelieve Verbist, Debby Thomas, Ellen Gomme, Els Hermans, Philippe Moerman, Tjalling Bosse, Frederic Amant
发表日期
2017/3/1
期刊
Clinical Cancer Research
卷号
23
期号
5
页码范围
1274-1285
出版商
American Association for Cancer Research
简介
Purpose: Uterine sarcomas are rare and heterogeneous tumors characterized by an aggressive clinical behavior. Their high rates of recurrence and mortality point to the urgent need for novel targeted therapies and alternative treatment strategies. However, no molecular prognostic or predictive biomarkers are available so far to guide choice and modality of treatment.
Experimental Design: We investigated the expression of several druggable targets (phospho-S6S240 ribosomal protein, PTEN, PDGFR-α, ERBB2, and EGFR) in a large cohort of human uterine sarcoma samples (288), including leiomyosarcomas, low-grade and high-grade endometrial stromal sarcomas, undifferentiated uterine sarcomas, and adenosarcomas, together with 15 smooth muscle tumors of uncertain malignant potential (STUMP), 52 benign uterine stromal tumors, and 41 normal uterine tissues. The potential …
学术搜索中的文章
T Cuppens, D Annibali, A Coosemans, J Trovik… - Clinical Cancer Research, 2017